Show simple item record

dc.contributor.authorRaphael, Jon
dc.contributor.authorAhmedzai, Sam
dc.contributor.authorHester, Joan
dc.contributor.authorUrch, Catherine
dc.contributor.authorBarrie, Janette
dc.contributor.authorWilliams, John
dc.contributor.authorFarquhar-Smith, Paul
dc.contributor.authorFallon, Marie
dc.contributor.authorHoskin, Peter J
dc.contributor.authorRobb, Karen
dc.contributor.authorBennett, Michael I
dc.contributor.authorHaines, Rebecca
dc.contributor.authorJohnson, Martin
dc.contributor.authorBhaskar, Arun K
dc.contributor.authorChong, Sam
dc.contributor.authorDuarte, Rui
dc.contributor.authorSparkes, Elizabeth
dc.date.accessioned2010-08-04T14:22:03Z
dc.date.available2010-08-04T14:22:03Z
dc.date.issued2010-05
dc.identifier.citationCancer pain: part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. 2010, 11 (5):742-64 Pain Meden
dc.identifier.issn1526-4637
dc.identifier.pmid20546514
dc.identifier.doi10.1111/j.1526-4637.2010.00840.x
dc.identifier.urihttp://hdl.handle.net/10541/109074
dc.description.abstractOBJECTIVE: This discussion document about the management of cancer pain is written from the pain specialists' perspective in order to provoke thought and interest in a multimodal approach to the management of cancer pain, not just towards the end of life, but pain at diagnosis, as a consequence of cancer therapies, and in cancer survivors. It relates the science of pain to the clinical setting and explains the role of psychological, physical, interventional and complementary therapies in cancer pain. METHODS: This document has been produced by a consensus group of relevant health care professionals in the United Kingdom and patients' representatives making reference to the current body of evidence relating to cancer pain. In the first of two parts, pathophysiology, oncological, pharmacological, and psychological treatment are considered. CONCLUSIONS: It is recognized that the World Health Organization (WHO) analgesic ladder, while providing relief of cancer pain towards the end of life for many sufferers worldwide, may have limitations in the context of longer survival and increasing disease complexity. To complement this, it is suggested that a more comprehensive model of managing cancer pain is needed that is mechanism-based and multimodal, using combination therapies including interventions where appropriate, tailored to the needs of an individual, with the aim to optimize pain relief with minimization of adverse effects.
dc.language.isoenen
dc.subjectCancer Painen
dc.subjectPain managementen
dc.subject.meshAnalgesics
dc.subject.meshNeoplasms
dc.subject.meshPain
dc.subject.meshPalliative Care
dc.subject.meshPhysicians, Family
dc.titleCancer pain: part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners.en
dc.typeArticleen
dc.contributor.departmentFaculty of Health, Birmingham City University, Birmingham, UK. jon.raphael@bcu.ac.uken
dc.identifier.journalPain Medicineen
html.description.abstractOBJECTIVE: This discussion document about the management of cancer pain is written from the pain specialists' perspective in order to provoke thought and interest in a multimodal approach to the management of cancer pain, not just towards the end of life, but pain at diagnosis, as a consequence of cancer therapies, and in cancer survivors. It relates the science of pain to the clinical setting and explains the role of psychological, physical, interventional and complementary therapies in cancer pain. METHODS: This document has been produced by a consensus group of relevant health care professionals in the United Kingdom and patients' representatives making reference to the current body of evidence relating to cancer pain. In the first of two parts, pathophysiology, oncological, pharmacological, and psychological treatment are considered. CONCLUSIONS: It is recognized that the World Health Organization (WHO) analgesic ladder, while providing relief of cancer pain towards the end of life for many sufferers worldwide, may have limitations in the context of longer survival and increasing disease complexity. To complement this, it is suggested that a more comprehensive model of managing cancer pain is needed that is mechanism-based and multimodal, using combination therapies including interventions where appropriate, tailored to the needs of an individual, with the aim to optimize pain relief with minimization of adverse effects.


This item appears in the following Collection(s)

Show simple item record